FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2601323564> ?p ?o ?g. }

• W2601323564 endingPage "2488" @default.
• W2601323564 startingPage "2488" @default.
• W2601323564 abstract "Abstract Background: Sickle cell disease (SCD) is caused by polymerization of Hemoglobin S (HbS), resulting in hemolysis and vaso-occlusion. No therapy achieving pancellular, direct inhibition of HbS polymerization is available. GBT440 is a novel small molecule which increases hemoglobin oxygen affinity and inhibits HbS polymerization and prevents sickling in vitro. This study explored safety, pharmacokinetics (PK) and pharmacodynamics (PD) of GBT440 in healthy volunteers (HV) and subjects with SCD. Methods: This randomized, placebo-controlled, double-blind, phase I/II study enrolled HV and SCD subjects (HbSS and HbSB0). A cohort of 8 subjects with other SCD genotypes (HbSC or HbS/β+thalassemia) is being enrolled. The study was conducted in three parts: Part A, single ascending doses, Part B, multiple ascending doses for 28 days and Part C, 90-day dosing. Longer term dosing (up to 6 months) is being evaluated. The primary endpoint was safety. Secondary endpoints included PK, PD and hematological effects. Results: New and updated results including up to 6 months of dosing and data on other SCD genotypes will be presented at the meeting. As of 26 July 2016, 38 SCD subjects had completed Part B (10 at 500 mg; 12 at 700 mg; 6 at 1000 mg; 10 received placebo [pbo]). An additional 16 SCD subjects have completed or are ongoing in Part C (6 at 700 mg: 6 at 900 mg; 4 on pbo). Enrollment is ongoing for SCD subjects with HbSC or HbS/β+thalassemia. Results are available for SCD subjects enrolled into Part B and Part C (700 mg). The SCD subjects include approximately 60% male, 40% female; 20% were on hydroxyrea (HU); 20% had 2 or more painful crises requiring hospitalization in the prior year; median age was 34 years (range, 20 to 56). There were no drug-related severe or serious adverse events; the majority of AEs were Grade 1 or 2. The most common treatment emergent AEs were headache, back pain and sickle cell crisis. All sickle cell crises on placebo or GBT440 occurred off treatment and were assessed as not related to study drug. PK exposures increased dose-proportionally; mean GBT440 whole blood half-life following multiple doses was approximately 1.5 days and RBC:plasma ratio was 75:1. GBT440-treated subjects demonstrated increased hemoglobin oxygen affinity (p50 shifted to the left towards the normal range), an increase in hemoglobin levels and a sustained decrease in unconjugated bilirubin during the 90 day treatment period (Figure 1, Table 1). Other markers of hemolysis improved concordantly (Table 1). Conclusions: GBT440 was well tolerated with dose-proportional PK and increases in hemoglobin oxygen affinity. GBT440 resulted in marked and sustained reduction in clinical markers of hemolysis and an increase in hemoglobin. These results are consistent with inhibition of HbS polymerization leading to decreased RBC damage, improved RBC lifespan and tissue oxygen delivery, and support further investigation of GBT440 as a potential disease-modifying therapy for SCD. Change from Baseline to Day 90 in Hemoglobin (GBT440 700 mg) Change from Baseline to Day 90 in Hemoglobin (GBT440 700 mg) Figure 1 Figure 1. Disclosures Lehrer-Graiwer: Global Blood Therapeutics: Employment, Equity Ownership. Mant:Quintiles: Employment. Dufu:Global Blood Therapeutics: Employment, Equity Ownership. Hutchaleelaha:Global Blood Therapeutics: Employment, Equity Ownership. Oksenberg:Global Blood Therapetics: Employment, Equity Ownership. Patel:Global Blood Therapeutics: Employment, Equity Ownership. Tonda:Global Blood Therapetics: Employment, Equity Ownership. Bridges:Global Blood Therapetics: Employment, Equity Ownership. Ramos:Global Blood Therapeutics: Employment, Equity Ownership." @default.
• W2601323564 created "2017-04-07" @default.
• W2601323564 creator A5009512674 @default.
• W2601323564 creator A5010415710 @default.
• W2601323564 creator A5012780955 @default.
• W2601323564 creator A5015207269 @default.
• W2601323564 creator A5033014045 @default.
• W2601323564 creator A5033198503 @default.
• W2601323564 creator A5040437391 @default.
• W2601323564 creator A5040935737 @default.
• W2601323564 creator A5049244658 @default.
• W2601323564 creator A5055599886 @default.
• W2601323564 creator A5057169108 @default.
• W2601323564 creator A5058779959 @default.
• W2601323564 creator A5062672479 @default.
• W2601323564 creator A5081670719 @default.
• W2601323564 creator A5088733732 @default.
• W2601323564 date "2016-12-02" @default.
• W2601323564 modified "2023-10-13" @default.
• W2601323564 title "Long-Term Dosing in Sickle Cell Disease Subjects with GBT440, a Novel HbS Polymerization Inhibitor" @default.
• W2601323564 doi "https://doi.org/10.1182/blood.v128.22.2488.2488" @default.
• W2601323564 hasPublicationYear "2016" @default.
• W2601323564 type Work @default.
• W2601323564 sameAs 2601323564 @default.
• W2601323564 citedByCount "11" @default.
• W2601323564 countsByYear W26013235642017 @default.
• W2601323564 countsByYear W26013235642018 @default.
• W2601323564 countsByYear W26013235642019 @default.
• W2601323564 countsByYear W26013235642020 @default.
• W2601323564 countsByYear W26013235642021 @default.
• W2601323564 countsByYear W26013235642023 @default.
• W2601323564 crossrefType "journal-article" @default.
• W2601323564 hasAuthorship W2601323564A5009512674 @default.
• W2601323564 hasAuthorship W2601323564A5010415710 @default.
• W2601323564 hasAuthorship W2601323564A5012780955 @default.
• W2601323564 hasAuthorship W2601323564A5015207269 @default.
• W2601323564 hasAuthorship W2601323564A5033014045 @default.
• W2601323564 hasAuthorship W2601323564A5033198503 @default.
• W2601323564 hasAuthorship W2601323564A5040437391 @default.
• W2601323564 hasAuthorship W2601323564A5040935737 @default.
• W2601323564 hasAuthorship W2601323564A5049244658 @default.
• W2601323564 hasAuthorship W2601323564A5055599886 @default.
• W2601323564 hasAuthorship W2601323564A5057169108 @default.
• W2601323564 hasAuthorship W2601323564A5058779959 @default.
• W2601323564 hasAuthorship W2601323564A5062672479 @default.
• W2601323564 hasAuthorship W2601323564A5081670719 @default.
• W2601323564 hasAuthorship W2601323564A5088733732 @default.
• W2601323564 hasConcept C111113717 @default.
• W2601323564 hasConcept C112705442 @default.
• W2601323564 hasConcept C126322002 @default.
• W2601323564 hasConcept C142724271 @default.
• W2601323564 hasConcept C168563851 @default.
• W2601323564 hasConcept C203092338 @default.
• W2601323564 hasConcept C204787440 @default.
• W2601323564 hasConcept C27081682 @default.
• W2601323564 hasConcept C2777288759 @default.
• W2601323564 hasConcept C2777799968 @default.
• W2601323564 hasConcept C2778917026 @default.
• W2601323564 hasConcept C71924100 @default.
• W2601323564 hasConcept C90924648 @default.
• W2601323564 hasConcept C98274493 @default.
• W2601323564 hasConceptScore W2601323564C111113717 @default.
• W2601323564 hasConceptScore W2601323564C112705442 @default.
• W2601323564 hasConceptScore W2601323564C126322002 @default.
• W2601323564 hasConceptScore W2601323564C142724271 @default.
• W2601323564 hasConceptScore W2601323564C168563851 @default.
• W2601323564 hasConceptScore W2601323564C203092338 @default.
• W2601323564 hasConceptScore W2601323564C204787440 @default.
• W2601323564 hasConceptScore W2601323564C27081682 @default.
• W2601323564 hasConceptScore W2601323564C2777288759 @default.
• W2601323564 hasConceptScore W2601323564C2777799968 @default.
• W2601323564 hasConceptScore W2601323564C2778917026 @default.
• W2601323564 hasConceptScore W2601323564C71924100 @default.
• W2601323564 hasConceptScore W2601323564C90924648 @default.
• W2601323564 hasConceptScore W2601323564C98274493 @default.
• W2601323564 hasIssue "22" @default.
• W2601323564 hasLocation W26013235641 @default.
• W2601323564 hasOpenAccess W2601323564 @default.
• W2601323564 hasPrimaryLocation W26013235641 @default.
• W2601323564 hasRelatedWork W1971885716 @default.
• W2601323564 hasRelatedWork W1992426253 @default.
• W2601323564 hasRelatedWork W2151922639 @default.
• W2601323564 hasRelatedWork W2159406923 @default.
• W2601323564 hasRelatedWork W2911677179 @default.
• W2601323564 hasRelatedWork W2915644342 @default.
• W2601323564 hasRelatedWork W3034286462 @default.
• W2601323564 hasRelatedWork W3166797618 @default.
• W2601323564 hasRelatedWork W4210913627 @default.
• W2601323564 hasRelatedWork W4288738052 @default.
• W2601323564 hasVolume "128" @default.
• W2601323564 isParatext "false" @default.
• W2601323564 isRetracted "false" @default.
• W2601323564 magId "2601323564" @default.
• W2601323564 workType "article" @default.